Renal Oximetry-Guided Anesthesia With Near-Infrared Spectroscopy for Improved Postoperative Outcomes
ROGAR
1 other identifier
interventional
80
1 country
1
Brief Summary
The trial is a prospective, randomized, single-blind, pilot study investigating whether near-infrared spectroscopy (NIRS)-guided optimization of intraoperative renal oxygen saturation reduces postoperative acute kidney injury (AKI) in patients undergoing elective hepatectomy. The trial will enroll 80 adults (≥45 years, American society of Aneshesiologists physical status I-III), randomizing them to either standard anesthesia management or NIRS-guided management where a predefined 6-step intervention protocol (volume optimization, vasoactive drugs, inotropes, heart rate management, transfusion, and FiO₂ management) is triggered if decreases \>10% from baseline. Primary outcomes are the incidence of AKI within 7 days and the 28-day Comprehensive Complication Index (CCI). The study aims to determine if real-time SrtO₂ monitoring and proactive intervention can prevent this serious complication, based on previous observational data linking renal desaturation to AKI risk.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1
Started Sep 2025
Shorter than P25 for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 9, 2025
CompletedFirst Posted
Study publicly available on registry
August 26, 2025
CompletedStudy Start
First participant enrolled
September 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
April 24, 2026
CompletedMay 8, 2026
May 1, 2026
5 months
August 9, 2025
May 5, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Actue kidney injury
An increase in serum creatinine of ≥26.5 μmol/L from baseline within 48 hours or an increase of ≥50% from baseline within 7 days
Postoperative Day 1-7
Comprehensive Complication Index
The co-primary outcome is the Comprehensive Complication Index (CCI) score, which includes all complications occurring from randomization to the 28-day follow-up period and calculated using the Clavien-Dindo classification (CDC).
Postoperative Day 1-28
Secondary Outcomes (7)
Total duration and proportion of time during surgery of renal desaturation
Intraoperative
Area under the curve for renal oxygen desaturation
Intraoperative
Use of vasoactive drugs
Intraoperative
Intraoperative blood pressure levels
Intraoperative
AKI grading
Postoperative Day 1-7
- +2 more secondary outcomes
Study Arms (2)
NIRS-guided anesthesia management group
EXPERIMENTALNIRS-guided management where a predefined 6-step intervention protocol (volume optimization, vasoactive drugs, inotropes, heart rate management, transfusion, and FiO₂ increase)
Standard anesthesia management
PLACEBO COMPARATORstandard anesthesia management
Interventions
NIRS-guided management where a predefined 6-step intervention protocol (volume optimization, vasoactive drugs, inotropes, heart rate management, transfusion, and FiO₂ increase)
Eligibility Criteria
You may qualify if:
- Age ≥ 45 years
- Scheduled for elective hepatectomy
- Planned for general anesthesia with endotracheal intubation
- BMI \< 30 kg/m2
- Preoperative ultrasound shows renal cortical to skin distance ≤ 4 cm
- ASA classification I-III
- Consenting to participate and signing informed consent
You may not qualify if:
- Liver transplantation surgery
- Preoperative renal dysfunction or requirement for dialysis treatment;
- Contraindications to vasoactive drugs such as norepinephrine or dopamine as determined by the clinician;
- Severe cardiopulmonary insufficiency (severe arrhythmia, heart failure, respiratory failure, chronic obstructive pulmonary disease), or a serious cardiovascular or cerebrovascular event within the last six months before randomization (such as acute heart failure, acute myocardial infarction, stroke, etc.);
- Patient refusal to participate or current participation in another experimental study;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Chinese PLA General Hospitallead
- Beijing Tsinghua Changgeng Hospitalcollaborator
Study Sites (1)
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof
Study Record Dates
First Submitted
August 9, 2025
First Posted
August 26, 2025
Study Start
September 1, 2025
Primary Completion
February 1, 2026
Study Completion
April 24, 2026
Last Updated
May 8, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share